Beatrice Lejeune

Chief Regulatory Officer

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Beatrice Lejeune is the Chief Regulatory Officer at InFlectis BioScience in France. Her research focuses on immunotherapy, inflammation, and neurodegenerative diseases, reflected in her recent articles on topics such as the effects of Sephin1 in ALS models and the anti-inflammatory properties of micro-immunotherapy in various conditions. She contributes significantly to understanding the interplay between inflammation and chronic diseases, including cancer and autoimmune disorders.

Articles (6)

Year:

2025

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Dieudonnee Togbe

Professor

CNRS Campus Orléans

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Beatrice Lejeune

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

Sephin1 reduces TDP-43 cytoplasmic mislocalization and improves motor neuron survival in ALS models

Jawbone Cavitation Expressed RANTES/CCL5: Case Studies Linking Silent Inflammation in the Jawbone with Epistemology of Breast Cancer.

BMP4 micro‐immunotherapy increases collagen deposition and reduces PGE2 release in human gingival fibroblasts and increases tissue viability of engineered 3D gingiva under inflammatory conditions

Potential Role of the Micro-Immunotherapy Medicine 2LALERG in the Treatment of Pollen-Induced Allergic Inflammation.

Pro-Inflammatory Cytokines at Ultra-Low Dose Exert Anti-Inflammatory Effect In Vitro: A Possible Mode of Action Involving Sub-Micron Particles?

The Micro-Immunotherapy Medicine 2LARTH® Reduces Inflammation and Symptoms of Rheumatoid Arthritis In Vivo.

Collaborators (1)

Dieudonnee Togbe

Make your next move.